PBE 📈 Invesco Dynamic - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46137V7872 • Health
PBE: Biotechnology, Pharmaceuticals, Genomics, Vaccines, Diagnostics, Therapies
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified. ‣ Company URL: http://www.invesco.com/us ‣ Domicile: United States
Additional Sources for PBE ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PBE ETF Overview
| Market Cap in USD | 254m |
| Category | Health |
| TER | 0.58% |
| IPO / Inception | 2005-06-23 |
PBE ETF Ratings
| Growth 5y | 23.5% |
| Fundamental | - |
| Dividend | 8.01% |
| Rel. Strength Industry | -78.7 |
| Analysts | - |
| Fair Price Momentum | 61.49 USD |
| Fair Price DCF | - |
PBE Dividends
| Dividend Yield 12m | 0.05% |
| Yield on Cost 5y | 0.06% |
| Annual Growth 5y | -16.64% |
| Payout Consistency | 26.7% |
PBE Growth Ratios
| Growth Correlation 3m | 6.5% |
| Growth Correlation 12m | 67.4% |
| Growth Correlation 5y | 20.4% |
| CAGR 5y | 3.54% |
| CAGR/Mean DD 5y | 0.20 |
| Sharpe Ratio 12m | -0.02 |
| Alpha | -21.38 |
| Beta | 0.90 |
| Volatility | 27.16% |
| Current Volume | 6.5k |
| Average Volume 20d | 5.6k |
What is the price of PBE stocks?
As of December 22, 2024, the stock is trading at USD 67.22 with a total of 6,500 shares traded.
Over the past week, the price has changed by -1.58%, over one month by -0.62%, over three months by -5.79% and over the past year by +5.84%.
As of December 22, 2024, the stock is trading at USD 67.22 with a total of 6,500 shares traded.
Over the past week, the price has changed by -1.58%, over one month by -0.62%, over three months by -5.79% and over the past year by +5.84%.
Is Invesco Dynamic a good stock to buy?
Neither. Based on ValueRay Analyses, Invesco Dynamic is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 23.50 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PBE as of December 2024 is 61.49. This means that PBE is currently overvalued and has a potential downside of -8.52%.
Neither. Based on ValueRay Analyses, Invesco Dynamic is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 23.50 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PBE as of December 2024 is 61.49. This means that PBE is currently overvalued and has a potential downside of -8.52%.
Is PBE a buy, sell or hold?
Invesco Dynamic has no consensus analysts rating.
Invesco Dynamic has no consensus analysts rating.
What are the forecast for PBE stock price target?
According to ValueRays Forecast Model, PBE Invesco Dynamic will be worth about 68.2 in December 2025. The stock is currently trading at 67.22. This means that the stock has a potential upside of +1.38%.
According to ValueRays Forecast Model, PBE Invesco Dynamic will be worth about 68.2 in December 2025. The stock is currently trading at 67.22. This means that the stock has a potential upside of +1.38%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 68.2 | 1.4% |